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Abstract: Autophagy is an intracellular degradation pathway for long-lived proteins and 
organelles. This process is activated above basal levels upon cell intrinsic or environmental 
stress and dysregulation of autophagy has been linked to various human diseases, including 
those caused by viral infection. Many viruses have evolved strategies to directly interfere 
with autophagy, presumably to facilitate their replication or to escape immune detection. 
However, in some cases, modulation of autophagy appears to be a consequence of the virus 
disturbing the cell’s metabolic signaling networks. Here, we summarize recent advances in 
research at the interface of autophagy and viral infection, paying special attention to 
strategies that human tumor viruses have evolved. 
Keywords:  autophagy; cancer; Epstein–Barr virus; hepatitis B virus; hepatitis C virus; 
human papillomavirus; human T-lymphotropic virus 1; Kaposi’s sarcoma-associated 
herpesvirus; Merkel cell polyomavirus 
 
1. Introduction 
1.1. Human Oncogenic Viruses 
Viruses are intracellular parasites that strictly depend on a host to replicate. Thus, after entry, they 
reprogram their host cells to meet their needs. For the host, the consequences of viral infection span a 
wide range from being asymptomatic to causing deadly disease. Approximately 10–15% of human 
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cancers are associated with viral infections [1]. Despite this substantial number, the list of human 
viruses that are clearly involved in the etiology of human tumors is rather short [2]. The first human 
tumor viruses to be identified is Epstein–Barr Virus (EBV) that has been linked to Hodgkin’s 
lymphoma, Burkitt’s lymphoma, nasopharyngeal carcinoma as well as other hematological 
malignancies in immunosuppressed individuals [3]. Hepatitis B (HBV) and C (HCV) viruses have 
been linked to hepatocellular carcinoma (HCC) [4], human papillomaviruses (HPVs) to cervical, anal, 
vulvar, vaginal, penile and oropharyngeal cancers as well as to squamous cell skin carcinomas in 
immunosuppressed patients [5], and the human T-lymphotropic virus 1 (HTLV-1) has been linked to 
adult T-cell leukemia (ATL) [6]. More recently identified human oncogenic viruses include Kaposi’s 
sarcoma-associated herpesvirus (KSHV) that causes Kaposi’s sarcoma, primary effusion lymphoma 
(PEL) and Castleman’s disease [7] and the Merkel cell polyomavirus (MCPyV) that has been linked to 
a rare but highly lethal skin cancer, Merkel cell carcinoma (MCC) [2] (Table 1). In addition to the 
viruses listed above, a number of other viruses have been reported to contribute to human cancers but 
these associations remain to be confirmed [8]. One interesting emerging candidate is the human 
cytomegalovirus (HCMV), which may modulate the carcinogenic phenotype of cancers, in particular 
glioblastoma. While HCMV encodes multiple proteins that can subvert the activities of cellular tumor 
suppressors, the clinical significance of the presence of HCMV sequences in these tumors remains 
controversial [9]. With the advent of deep sequencing, one might expect that viral sequences and/or 
transcripts will be detected in even more cancer types but the mere discovery of viral sequences in a 
tumor does not imply a causative relationship. It is worth noting that while infections with one of the 
established human tumor viruses is associated with a majority or at least a significant percentage of the 
respective cancers, some of these cancers can also arise without viral infection.  
Although human tumor viruses comprise a diverse group of viruses (Table 1), most of them share 
the ability to establish long-term latent or persistent infections. In this state, the viral genome is 
maintained as an episomal element or as an integrated genome copy within a host chromosome, and is 
replicated along with the host cellular genome by the host’s DNA replication machinery. Structural 
viral proteins required for virion formation are not, or at least not abundantly synthesized during 
latency [2]. This most likely decreases the vulnerability of virally infected cells for elimination by the 
immune system.  
To ensure viral survival and propagation, progeny virus needs to be generated and the host cell has 
to produce the necessary enzymes and metabolites. Therefore, many tumor viruses encode proteins 
that promote cell cycle entry, counteract programmed cell death, subvert cellular differentiation and/or 
interfere with immune signaling [10]. However, virtually all of the cellular pathways targeted by these 
viruses can contribute to carcinogenesis. In some cases, particularly with HPV associated cervical 
carcinoma and MCPyV induced Merkel cell carcinoma, viral oncogenesis represents a consequence of 
a non-productive infection, i.e., the expression of viral proteins in the absence of the viral life cycle 
and many of these tumors only express a subset of viral proteins or fragments thereof from integrated 
viral subgenomes [11]. Cells 2012, 1  
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Table 1. Human tumor viruses, their associated cancers, and mechanisms of autophagy 
modulation. 
Associated  
cancer types 
Mechanism of interference with autophagy and/or  
autophagy-regulating pathways 
Epstein–Barr virus (EBV) Herpesviridae
Burkitt’s and Hodgkin- 
and non-Hodgkin 
lymphomas, 
nasopharyngeal 
carcinoma, 
lymphoproliferative 
diseases  
BILF1  PKR inhibition  may inhibit autophagy [12] 
LMP1  JNK activation may promote autophagy [13–15] 
LMP1  NF-B activation  inhibits autophagy in B cells [16] 
LMP1  p38 activation  may inhibit autophagy [17] 
LMP1  activation of UPR signaling  autophagic markers [18,19] 
LMP1/LMP2A  PI3K/mTOR activation  may inhibit autophagy [20–24] 
ZTA  NF-B inhibition  ? [25] 
Hepatitis B virus (HBV) Hepadnaviridae 
Hepatocellular 
carcinoma 
HBx  increased Beclin-1 transcription  autophagic markers [26] 
HBx  increased LC3-lipidation and VPS34 activity  incomplete autophagic 
response [27] 
HBx  interacts with p53  may inhibit autophagy [28] 
HBx  p38 activation  may inhibit autophagy [29] 
HBx/LHBs/MHBs  ERK activation  may inhibit autophagy [30–32] 
LHBs  PI3K/AKT/mTOR activation  may inhibit autophagy [32–34] 
LHBs/MHBs  NF-B activation  ? [31,35] 
SHBs  activation of UPR signaling  incomplete autophagic response [33,36] 
SHBs  interacts with LC3  incomplete autophagic response [36] 
Hepatitis C virus (HCV) Flaviviridae 
Hepatocellular 
carcinoma 
Core/NS3  ERK activation  may inhibit autophagy [37,38] 
Core/NS3  JNK activation may promote autophagy [37,38] 
Core/NS3/NS4B/NS5A  NF-B activation  ? [37,39,40] 
Core/NS3  p38 activation  may inhibit autophagy [37,38] 
Core/NS3/NS5A  interact with p53  may inhibit autophagy [41–45] 
Core/NS4B  AKT activation  may inhibit autophagy [46] 
NS3  interacts with IRGM  increases autophagic markers [47] 
NS4B  activation of UPR signaling  autophagic markers [48] 
NS4B  interacts with Rab5 and VPS34  incomplete autophagic response [48] 
NS5A  PI3K/mTOR activation  may inhibit autophagy [49,50] 
NS5A  ERK inhibition  may activate autophagy [50,51] 
NS5A  PKR inhibition  may inhibit autophagy [52] 
NS5A  p38 inhibition  may promote autophagy [53] 
NS5B  interacts with ATG5  ? [54] 
?  increased Beclin-1 expression  autophagic markers [55] Cells 2012, 1  
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Table 1. Cont. 
Associated  
cancer types 
Mechanism of interference with autophagy and/or  
autophagy-regulating pathways 
Human papillomavirus, high-risk types (HPV) Papillomaviridae
Cervical, anal and 
penile cancers, head 
and neck cancers 
E5  p38 activation  may inhibit autophagy [56] 
E5/E6/E7  inhibit XBP1-splicing under basal conditions  ? [57] 
E6  sustained AKT/mTORC1 activity  may inhibit autophagy [58,59] 
E6  inhibits p53  may inhibit autophagy [60] 
E6/E7  ERK activation  may inhibit autophagy [61] 
E7  AKT activation  may inhibit autophagy [62,63] 
E7  NF-B inhibition  ? [64–66] 
E7  JNK inhibition  may inhibit autophagy [67] 
E7  ?  autophagic markers [68] 
Human T-lymphotropic virus (HTLV-1) Retroviridae 
Adult T-cell leukemia 
Tax  JNK activation  may promote autophagy [69] 
Tax  sustained AKT/mTORC1 activity  may inhibit autophagy [70,71] 
Tax  p38 activation  may inhibit autophagy [69] 
Tax  activation of UPR signaling  may promote autophagy [72] 
Tax  inhibits p53  may inhibit autophagy [73] 
Tax+HBZ  NF-B activation  ? [74–77] 
Kaposi’s sarcoma associated herpesvirus (KSHV) Herpesviridae
Kaposi’s sarcoma, 
pleural effusion 
lymphoma, 
multicentric 
Castleman’s disease 
K1  PI3K/AKT/mTOR activation  may inhibit autophagy [78–80] 
K15  ERK activation  may inhibit autophagy [81] 
K15  p38 activation  may inhibit autophagy [81] 
LANA  inhibits p53  may inhibit autophagy [82] 
ORF45  sustained ERK/RSK activity  autophagy [83,84] 
ORF49  JNK activation  may promote autophagy [85] 
ORF49/vGPCR  p38 activation  may inhibit autophagy [85,86] 
RTA  ?  increased autophagy [87] 
vBCL-2  interacts with Beclin-1  autophagy inhibition [88,89] 
vFLIP  interacts with ATG3  autophagy inhibition [90] 
vFLIP/K15/ORF75/miR-K1/vGPCR7/vIRF3  NF-B activation  ? [81,91–96] 
vGPCR  PI3K/mTORC1 activation  may inhibit autophagy [97] 
vIRF2/vIRF3  PKR inhibition  may inhibit autophagy [98,99] 
vIRF3  NF-B inhibition  ? [93,100] 
Merkel cell polyomavirus (MCPyV) Polyomaviridae 
Merkel cell carcinoma  Small T  mTORC1 activation  may inhibit autophagy [75]
The table lists established human tumor viruses, their associated malignancies and the autophagy-related 
proteins and autophagy-regulating signaling pathways they modulate. Note that in many studies, an effect on 
autophagy has not been explicitly investigated or conclusively and comprehensively validated [101]. With 
regard to the current literature, it is difficult to predict effects of NF-kB activation on autophagy. ERK, JNK 
and p38 modulate or have been suggested to modulate autophagy via pathways other than NF-kB, and the 
predictions listed in this table are based on these mechanisms [102–104].  Cells 2012, 1  
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1.2. Autophagy—Basic Function and Role in Human Disease 
Autophagy is a key homeostatic process conserved across all eukaryotic cells. The term literally 
translated means “self-eating” and describes a degradation pathway for intracellular structures via the 
lysosomal compartment. Although several mechanistically distinct forms of autophagy are 
distinguished (macro-, micro- and chaperone-mediated autophagy (reviewed in [105]) “autophagy” is 
commonly (and also for the purpose of this review) used synonymously with macroautophagy, the 
most widely studied subtype. (Macro)autophagy is characterized by formation of large, double 
membraned vesicles, so called autophagosomes, that sequester bulk portions of cytoplasm and, after 
closure, fuse with lysosomes so that the cargo can be degraded by lysosomal enzymes. This process 
takes place at a low basal level under physiologic conditions and facilitates turnover of long-lived 
proteins and organelles. However, upon exposure to environmental and endogenous stressors, such as 
nutrient- and growth factor deprivation, hypoxia, high temperature or organelle damage, autophagy is 
upregulated. Autophagy primarily represents a pro-survival mechanism, but in complex multicellular 
organisms, it serves additional purposes, including a role in adaptive and innate immunity. Autophagy 
has also been linked to programmed cell death, however, it is controversial at present whether the 
phenomenon of autophagic cell death actually exists [106]. Deregulation of autophagy has been 
implicated in a variety of human diseases including neurodegenerative diseases, cardiac disease, liver 
disease, myopathies, cancer and bacterial and viral infection [105]. Human tumors associated with the 
viruses mentioned above represent the interface between cancer and infectious diseases. Thus, 
autophagy may play an especially multifaceted role in virus-associated malignancies since it has pro- 
and anti-tumorigenic as well as pro- and anti-viral functions.  
1.3. Components of the Mammalian Autophagy Machinery 
On the molecular level, autophagy is mediated by the so-called Atg-genes/proteins, most of which 
were originally identified in genetic screens in the yeast Saccharomyces cerevisiae [107]. Of the   
35 Atg-proteins described to date, 21 function in all autophagy-related processes or specifically   
in non-selective bulk macroautophagy, while 14 Atg-proteins are required only for specialized 
subtypes such as pexophagy or mitophagy or the yeast-specific cytoplasm to vacuole targeting (Cvt) 
pathway [108–112]. Mammalian cells possess structural or functional homologs for at least 16 of the 
21 “core” Atg-proteins and a few vertebrate- or mammalian-specific autophagy factors such as   
Ambra-1 or ATG101 [108,113–115]. An overview of the autophagy pathway in mammalian cells is 
presented in Figure 1.  
In this review, we summarize our current knowledge on the particular strategies that human 
tumor viruses have evolved to interface with the host cell autophagy machinery and with autophagy-
regulating signaling pathways. We first examine the role of autophagy on the viral life cycle and 
subsequently describe mechanisms by which tumor viruses modulate this process. Yet, it should be 
emphasized that most of the virus—host cell interactions discussed below are not specific to human 
tumor viruses but have been described for non-tumorigenic viruses as well.  Cells 2012, 1  
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Figure 1. Schematic representation of the autophagy pathway in mammalian cells and 
interactions with viral proteins.  
 
The Atg-proteins can be grouped into four (or into six, according to other authors, e.g., [116]) functional 
modules that mediate the major steps of autophagy [117]: (1) An autophagy initiation complex consisting of 
the Serine/Threonine kinase ULK1 (or its close relative ULK2), and the regulatory proteins ATG13, focal 
adhesion kinase family interacting protein of 200 kD (FIP200) and ATG101 [116]; (2) A class III 
phosphatidylinositol 3-kinase (PI3K), VPS34, which, in cooperation with its interaction partners, facilitates 
vesicle nucleation. There are at least three biochemically and functionally distinct class III PI3K-complexes 
in mammalian cells, which share a common core comprising VPS34 itself and ATG6/Beclin-1 as well as 
p150 and Ambra-1 (omitted for clarity). The first complex comprises the core and ATG14L/Barkor and 
mediates autophagosome nucleation. The second complex, containing the core and UV irradiation resistance 
associated protein  (UVRAG) may be involved in autophagosome extension and/or other endosomal 
pathways [118]. The third complex, in which the core is associated with UVRAG and RUN domain and 
cysteine-rich domain containing Beclin-1 interacting protein (Rubicon) inhibits autophagosome and 
endosome maturation; (3) Two interconnected ubiquitin-like conjugation systems involved in autophagosome 
expansion and cargo recruitment. In these systems, the E1- and E2-like enzymes, ATG7 and ATG10, 
respectively, facilitate conjugation of the ubiquitin-like protein ATG12 to ATG5. This ATG5-ATG12 
conjugate is localized to the expanding autophagosomal membrane by ATG16L and potentially serves as the 
E3-ligase in the second conjugation system, which facilitates lipidation of the peripheral membrane protein 
LC3. Conjugation of LC3 further requires proteolytic processing by ATG4, as well as the E1-like enzyme 
ATG7 and another E2-like enzyme, ATG3 [117]. (4) A membrane trafficking and recycling system whose 
components are still poorly characterized functionally and include WD repeat domain phosphoinositide-
interacting protein 1 (WIPI1), which binds phosphatidylinositol-3-phosphate (the product of the VPS34-lipid Cells 2012, 1  
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kinase reaction) and the putative membrane carrier protein ATG9 as well as another transmembrane protein, 
VMP1, and ATG2 (omitted for clarity) [117]. Some substrates are marked for autophagic degradation by 
ubiquitination, and both ubiquitinated and non-ubiquitinated cargo can be recruited to the autophagosome by 
LC3-interacting adaptor proteins such as p62/sequestosome 1 [119]. Autophagic adaptors are especially 
important in selective forms autophagy and may also play a role in xenophagy of viral proteins [120]. Viral 
proteins that have been reported to physically interact with components of the autophagy machinery are 
depicted in this schematic drawing. Please note that upstream signaling pathways that target the ULK1-
autophagy initiation complex or one of the other Atg-proteins and viral proteins interfering with them were 
omitted from this figure for clarity but are shown in detail in Figures 3–5. Some of the interactions of viral 
proteins with host cell autophagy-factors may require further experimental validation (see main text). Light 
grey rounded rectangles—host cell proteins with enzymatic activity; dark grey rounded rectangles—other 
host cell proteins; colored hexagons—viral proteins; : activation; to : inhibition. 
2. Benefits of Autophagy Modulation on the Viral Life Cycle
As with viral reprogramming of the host cell in general, viral interference with autophagy primarily 
aims to promote the viral life cycle. This includes avoiding detection by the immune system and 
creating a cellular environment favorable for viral replication. Autophagy is increasingly recognized as 
an important part of both innate and adaptive immune responses, which pathogens have to escape in 
order to successfully establish and sustain an infection [121]. This clearly provides a rationale for 
viruses to block autophagy. Yet, with regard to viral replication, the autophagy machinery appears to 
be beneficial rather than harmful to certain viruses, and these therefore activate rather than inhibit 
autophagy-like processes (Figure 2). The small but diverse set of human tumor viruses contains 
examples for both autophagy-inhibitors and autophagy-inducers. 
2.1. Viral Modulation of Autophagy-Mediated Immune Defense Mechanisms  
It has been speculated that autophagy, an ancient mechanism that allows survival during nutrient 
deprivation, further developed during evolution to provide protection against additional forms of stress 
that multicellular organisms are exposed to, including infection by bacterial, protozoan and viral 
pathogens [121]. Research in recent years has provided conclusive evidence for autophagy playing a 
crucial role in host cell immunity [121]. Atg-proteins, however, may also function in immunity 
independently of their role in autophagy, as reported for ATG5 in macrophages infected with the 
protozoon Toxoplasma gondii [122].  
In general, the regulation of autophagy (or of Atg-proteins) by immune signals is reciprocal and 
complex, and each can either induce or suppress the other [121]. Autophagy contributes to host defense 
in at least three ways (Figure 2). First, it targets pathogens for lysosomal degradation in a process that, 
more appropriately, is also referred to as xenophagy (eating of foreign matter) [123]. There is evidence 
that among the human tumor viruses, EBV is subject to xenophagy in epithelial cells [124].  
Second, in the adaptive immune response, autophagy facilitates presentation of viral antigens on 
major histocompatibility complex (MHC) class II-molecules, which are usually loaded with antigen 
peptides derived from endocytosed pathogens [125–127]. Autophagy-mediated presentation on MHC 
class II has been originally described in lymphoblastoid cell lines (LCLs) for antigen peptides derived 
from the EBV nuclear antigen 1 (EBNA1) [125]. However, EBNA1-derived antigen processing via the Cells 2012, 1  
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autophagy-MHC class II-route appears to be epitope specific, and occurs only at a very low level. The 
latter may be due to the fact that EBNA1 localizes to the nucleus where it seems to be largely 
protected from autophagy [128]. Evidence for the in vivo importance of the autophagy-MHC class II 
pathway was provided by a study that demonstrated impaired MHC class II antigen-processing 
and -presentation in mice with dendritic cell specific knockout of the essential autophagy gene 
Atg5  [129]. A more recent study further suggests that viral antigens that are generated via an 
autophagy-like process can also be presented on MHC class I. However, this has only been reported 
during late stages of herpes simplex virus 1 (HSV-1) infection in macrophages [130]. 
Figure 2. Autophagy and infection by human tumor viruses. 
 
The eight established human tumor viruses interfere with a variety of host cell signaling pathways, including 
immune signaling pathways and pathways regulating cell growth and survival, often in response to nutrient 
availability (see Figures 3 and 4). See main text for details. Note: In this figure, and frequently in the 
literature, the term “autophagy” is used to generally denote biological processes that involve Atg-proteins, 
even if genuine autophagy (i.e., degradation of intracellular macromolecules/structures) was not formally 
examined or if the late degradation steps in the pathway appeared to be blocked (for example in several 
studies on HBV and HCV modulation of autophagy, see main text for details). Light grey rounded 
rectangles—host cell kinases; dark grey rounded rectangles—other host cell proteins; colored hexagons—
viruses/viral proteins. 
 
Lastly, autophagy affects multiple innate immune signaling pathways. For example, autophagic 
vesicles in plasmacytoid dendritic cells can deliver cytosolic viral replication intermediates to acidified 
endosomes where they activate Toll-like receptor 7 (TLR7) and induce production of interferon  
(IFN) [131]. Conversely, TLR7 and various other TLRs, including TLRs 3 and 4 [132] as well as Cells 2012, 1  
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TLRs 1, 5 and 6 [133] have been reported to mediate autophagy induction in cultured macrophages 
when treated with the appropriate TLR-ligands. Some of the TLRs capable of signaling to the 
autophagy machinery also can be activated by some of the human tumor viruses including EBV, 
KSHV, HCV and HTLV-1 [134–137].  
Another innate immunity signaling pathway triggered by viral infection comprises the   
double-stranded RNA sensing kinase PKR. PKR phosphorylates the -subunit of the eukaryotic 
translation initiation factor 2 (eIF2), which inhibits translation of host cell and viral mRNAs and 
stimulates autophagy [138]. The precise molecular events that lead to increased autophagy 
downstream of eIF2 are presently unknown [139]. PKR is clearly required for autophagy-induction 
in response to HSV-1 infection [140], yet, several other viruses also encode proteins that inhibit PKR 
signaling [141], including EBV BILF1 [12], KSHV viral interferon regulatory factors 2 and 3 
(vIRF2/3) [98,99] and HCV non-structural protein 5A [52] (Figure 2). This supports the hypothesis 
that PKR plays an important role in virus-induced autophagy in general.  
While the studies cited above demonstrate a positive role for autophagy in host defense, two more 
recent reports provided evidence that HCV utilizes, rather than inhibits the autophagy machinery to 
quench an antiviral immune response [142,143]. In particular, HCV-infection and Atg-proteins were 
found to synergistically suppress expression of interferon  (IFN  or of IFN-inducible genes. These 
events are normally triggered upon exposure to HCV-derived pathogen associated molecular   
patterns [142], in cellular systems where HCV-infection increased autophagic markers [142,143] 
(Figure 2). It is unclear how inhibition of the IFN-regulated immune response by HCV-activated 
autophagy can be reconciled with the above mentioned predicted inhibition of PKR-induced autophagy 
by HCV NS5A [52], It is noted, that the literature on HCV and autophagy is particularly controversial 
in many respects. This may be due to the use of different cell lines/sublines and/or of different   
HCV-strains [144]. It is not clear, however, whether HCV genotypes indeed differ in their ability to 
induce autophagy [145] or not [55,146]. 
2.2. Virally Induced Autophagy and Replication
Some of the processes that are mediated by the autophagy machinery, such as antigen-processing or 
xenophagy, represent a threat to many pathogens, which, in turn, have adapted to this host response 
and in some cases, even found ways to take advantage of the Atg-proteins. A prominent example 
among the human tumor-associated viruses is provided by HCV. As discussed above, HCV may 
exploit the autophagy machinery to counteract an immune response [142,143]. Beyond that, multiple 
studies have reported that efficient HCV replication depends on Atg-proteins [55,142,146–148]. 
However, the various groups differ in their conclusions on the precise stage of infection during which 
Atg-proteins are required. Dreux et al. initially reported that replication efficiency in Huh7 cells was 
reduced when subgenomic HCV replicons were introduced after depletion of Atg-proteins [147]. 
Depletion of Atg-proteins in cells that already contained HCV subgenomic replicons, however, did not 
affect HCV RNA and protein levels. Thus, the authors concluded that the autophagy machinery is 
required for initiation of HCV replication but is dispensable once infection has been established [147]. 
A more recent study confirmed that Atg-proteins facilitate HCV replication upon initial   
infection [142], but there are conflicting reports on whether they are required for replication in infected Cells 2012, 1  
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cells [142,146–148]. Some studies imply that this is the case, since HCV viral particle release and 
survival of HCV-infected cells were decreased in the absence of Atg-proteins [142,143,145,148]. 
Clearly, additional studies are required to elucidate the basis for these discrepancies.  
How the autophagy machinery supports HCV replication is presently unclear. For several other 
positive-strand RNA-viruses, such as poliovirus, dengue virus and mouse hepatitis virus, which 
subvert the autophagy machinery to promote their life cycles, colocalization of viral proteins or RNA 
with markers of autophagy-related vesicles has been observed. This is consistent with the model that 
the membranes of these vesicles provide a scaffold for the viral replication complex [149–153]. 
However, in case of HCV, currently available data varies with regard to whether and in which stage of 
infection there is colocalization of viral replication factors with autophagosome-like vesicular 
membranes [55,147,148,154].  
HBV replication also appears to depend on the autophagy machinery since replication was decreased 
when HBV-transfected Huh7.5-cells were treated with the autophagy inhibitor 3-methyladenine (3-MA) 
or when VPS34 or ATG7 were depleted [27]. Studies by the same group in HBV-transgenic mice with 
liver specific knockout of the critical autophagy-regulator Atg5 further suggest that the autophagy 
machinery is required for efficient HBV DNA replication in vivo [155]. In contrast, another group 
found that autophagy inhibition predominantly affected viral envelopment, rather than DNA 
replication [36]. Whether these different results are due to different sublines of Huh7 or different HBV 
strains used by the two groups, as suggested by Tian et al. remains to be determined. 
Both HCC-associated viruses, HBV [27,36] and HCV [55,146], have been reported to induce 
autophagic markers in infected cells, however, without enhancing degradation of autophagy-substrates 
such as long lived proteins or p62. In case of HCV the initial reports cited above have been both 
substantiated and debated by more recent studies that provided evidence either for the incomplete 
autophagic response being due to impaired maturation of HCV-induced autophagosome-like   
vesicles [145] at late stages or for these vesicles actually being capable of mediating autophagic 
degradation of their cargo [142,156]. The study by Vescovo et al. suggests a partial explanation for 
this discrepancies: HCV-induced autophagy seems to predominantly target lipids, whereas turnover of 
organelles or proteins, which is commonly examined in autophagic flux assays [101] is largely 
unaffected by the virus. 
In KSHV infection, viral particles are produced only in the lytic phase. Overexpression of the 
replication and transcription activator, RTA, the master regulator of the latent-to-lytic switch increases 
LC3 conversion and autophagic flux in 293T- and BJAB cells [87]. Conversely, treatment with the 
autophagy inhibitor 3-MA or Beclin-1 depletion inhibited expression of RTA-induced lytic genes, and 
diminished viral genome replication in a RTA-overexpressing PEL cell line. The mechanism(s) by 
which RTA increases autophagy and how autophagy subsequently facilitates lytic replication remain to 
be determined [87]. As discussed below, KSHV encodes two other proteins, vFLIP and vBcl-2 that 
inhibit autophagy. Since vFLIP is expressed during both the latent and lytic phases of the viral life 
cycle [157], one might speculate that vFLIP inhibition of autophagy contributes to maintenance of 
latency. VBcl-2 expression increases early in the lytic phase [158], and hence both vFLIP and vBcl-2 
may serve to limit RTA-driven autophagy and lytic replication. In summary, KSHV may have 
developed multiple strategies to tightly control induction of lytic replication by modulating autophagy.  Cells 2012, 1  
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3. Mechanisms of Viral Interference with Autophagy
As outlined above, modulation of autophagy apparently provides certain advantages to viral 
invaders. Yet, only very few viruses encode proteins that directly interact with components of the 
autophagy machinery (Figure 2). More commonly, viruses target autophagy-regulating upstream 
signaling pathways, including immune signaling pathways [141]. 
3.1. Viral Oncoproteins Directly Targeting the Autophagy Machinery
3.1.1. Beclin-1—A Popular Target with Viral Proteins 
Beclin-1 was discovered in a yeast 2-hybrid screen for interaction partners of the anti-apoptotic 
protein Bcl-2 [88]. Beclin-1 was the first mammalian Atg protein to be identified and the first Atg 
protein that was established as a tumor suppressor [118]. Binding of cellular Bcl-2 (cBcl-2) and of the 
viral Bcl-2 homologs encoded by KSHV (termed vBcl-2) [158,159] and murine -herpes virus 68, 
 HV68 (termed M11) [160] to Beclin-1 suppresses autophagy [89,161]. EBV also encodes two Bcl-2 
homologs, BHRF1 [162] and BALF1 [163], but their potential interactions with Beclin-1 have not yet 
been examined. Upon starvation, cBcl-2 is phosphorylated by c-Jun N-terminal kinase 1 (JNK1), 
which causes disruption of the cBcl-2/Beclin-1 complex. In contrast, vBcl-2 lacks the relevant JNK 
phosphorylation sites [103] and, therefore, it constitutively associates with Beclin-1 to inhibit 
autophagy. It is interesting to note that several viral proteins including the EBV latent membrane 
protein 1 (LMP1) [13–15], KSHV ORF49 [85], HCV core and NS3, and HTLV-1 Tax [69] can 
activate the JNK signaling pathway, and this is predicted to activate Beclin-1 dependent autophagy. 
Conversely, expression of the HPV oncoprotein E7 can diminish JNK activation [67]. 
Another difference between cBcl-2 and vBcl-2 is that cBcl-2 disrupts the Beclin-1/UVRAG 
complex, whereas vBcl-2 does not, and instead forms a higher order Beclin-1/UVRAG/vBcl-2 
complex [161]. These results suggest that cBcl-2 and vBcl-2 may inhibit Beclin-1 dependent 
autophagy by different mechanisms: cBcl-2 may function by preventing Beclin-1 from associating 
with VPS34, whereas the precise molecular events by which vBcl-2 inhibits autophagy remain to be 
determined. Regardless, however, the fact that Beclin-1 is an established tumor suppressor suggests 
that its inhibition by tumor virus proteins such as vBcl-2 importantly contributes to host cell 
transformation [141]. 
As indicated above, Beclin-1 is a common target among viruses that modulate autophagy. Other 
viral proteins that associate with Beclin-1 include the ICP34.5 neurovirulence protein of the   
-herpesvirus HSV-1 [164], HIV-1 Nef [165] and the Influenza virus M2 protein [166]. While 
ICP34.5 association with Beclin-1 has been linked to inhibition of autophagy [167], it remains to be 
determined whether association of HIV-1 NEF or Influenza virus M2 with Beclin-1 inhibit autophagy. 
3.1.2. ATG3 Binding to FLIP-Proteins 
In addition to inhibiting autophagy through formation of a vBcl2/Beclin-1 complex, KSHV also 
blocks this process via its FLICE-like inhibitor protein, vFLIP (encoded by ORF71/K13). vFLIP and 
its cellular counterpart cFLIP, inhibit death receptor-induced apoptosis [168,169] and also suppress Cells 2012, 1  
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starvation- or rapamycin induced formation of LC3-decorated vesicles and cell death associated with 
autophagy [90]. Of note, the anti-autophagic activity of vFLIP and cFLIP were independent of their 
anti-apoptotic activities, and both vFLIP and cFLIP were found to bind the autophagy-protein ATG3 
competitively with LC3. For vFLIP, it was shown that the ability to interact with ATG3 was required 
for inhibition of cell death associated with autophagy [90]. 
3.1.3. Interactions of Viral Proteins with Other Autophagy-Regulating Proteins 
Biochemical evidence suggests interactions of various HBV- and HCV-proteins with components 
of the autophagy machinery. In particular, HBV X-protein (HBx) was shown to interact with VPS34 [27] 
and the small surface protein SHBs with LC3 [36]. In addition, HCV non-structural protein 3 (NS3) 
was found to associate and to colocalize with the immunity-associated GTPase family M protein 
(IRGM) [47], a known regulator of autophagy in response to bacterial infections [170]. NS4B 
coprecipitated with exogenous Rab5 and VPS34 [48] and NS5B was shown to coprecipitate with the 
ATG5-protein when overexpressed in yeast, and GFP-ATG5 and NS5B colocalized in Huh-7 cells [54]. 
Yet, several other groups working with various Huh-7 sub-lines infected with various HCV isolates 
observed little or no colocalization of various HCV-proteins such as core, NS3, NS4A/B and NS5A 
with autophagic marker proteins [55,145,146,148]. 
In addition to targeting autophagy regulators via protein-protein-interactions, HBV and HCV may 
also modulate autophagy through transcriptional activation of Beclin-1 expression. While in case of 
HBV, reporter assays suggested that HBx may transactivate the Beclin-1 promoter [26], mechanistic 
details of how HCV increased Beclin-1 expression remain to be determined [55].  
3.2. Autophagy-Regulating Signaling Pathways Targeted by Viral Oncoproteins
Autophagy is activated above basal levels in response to diverse environmental and physiological 
stressors such as nutrient- or growth factor deprivation, hypoxia, ER- and redox stress, organelle 
damage or pathogen infection [121]. This implies that autophagy is tightly connected to cellular 
metabolism and to diverse stress-sensitive signaling pathways. Yet, the precise molecular links 
between these pathways and the autophagy machinery have not yet been fully elucidated. In addition, 
virtually all the major cellular stress-sensing signaling pathways have been implicated in human 
cancer, and most of these pathways are also modulated by tumor viruses. In this section, we describe 
how viruses disturb some of the central stress-sensing host cell signaling pathways and discuss 
potential effects on autophagy. 
3.2.1. PI3K-AKT and mTORC1 Signaling 
The PI3K-AKT signaling pathway is activated downstream of growth factor receptors such as 
insulin-receptor and epidermal growth factor receptor (EGFR) and regulates several key aspects of cell 
physiology including cell cycle, metabolism and apoptosis (Figure 3). Activation of PI3K-AKT 
signaling promotes cell growth, proliferation and survival [171]. A central mediator of this pathway 
with regard to cell growth is the (m)TOR-complex 1 (mTORC1), a multiprotein complex comprising 
the Ser/Thr kinase mammalian target of rapamycin (mTOR) and regulatory proteins Raptor, GL, Cells 2012, 1  
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PRAS40 and Deptor (reviewed in [104]). ERK signaling, decreased AMPK signaling and availability 
of amino acids also activate mTORC1 (see below). mTORC1 supports cell growth by activating 
mRNA translation and ribosome biogenesis and by inhibiting autophagy [104]. In fact, inhibition of 
mTORC1 and its counterparts in other organisms is sufficient to activate autophagy even in the 
presence of nutrients [172]. Although TOR has long been known to be a key suppressor of   
autophagy [172], the mechanisms by which it regulates this process in mammalian cells have much 
more recently been delineated and the autophagy-initiating kinase ULK1 was identified as an 
mTORC1-substrate (for review, see [116] (Figure 3). While mTOR is rarely mutated in human   
cancers [173], alterations in PI3K-AKT signaling are among the most frequent alterations observed in a 
wide variety of tumors [174]. Such cancers are expected to have dysregulated mTORC1 signaling and 
dysregulated autophagy. Autophagy dysregulation by this pathway may be common in virus-associated 
malignancies, too. Even though the mTOR kinase itself does not seem to be a direct target of any viral 
protein, all the known human tumor viruses appear to interfere with PI3K-AKT-mTOR signaling, most 
likely to exploit the growth- and survival promoting function of these pathways. Tumors with 
hyperactive mTORC1 may be sensitive to treatment with mTOR(C1)-inhibitors such as rapamycin, 
and indeed, such drugs have been suggested for treating infections and/or tumors caused by   
EBV [175], KSHV [176,177], HBV [178], HCV [179], HPV [180] and HTLV-1 [181,182].  
EBV LMP1 mimics a ligand-independent, constitutively active CD40 receptor [183] and is 
sufficient for transformation of rodent cells and primary B lymphocytes in vitro [184,185] and   
in vivo [186]. LMP1 was shown to activate the PI3K-mTOR pathway in B cell lines [21] and   
LMP1-expression was positively correlated with phosphorylation of mTOR and its substrates 
ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein   
(4E-BP1) in nasopharyngeal carcinoma patient samples [20]. The second EBV encoded transmembrane 
protein, LMP2 [187], or more precisely, the LMP2A splice variant, is dispensable for B cell 
immortalization in vitro [188], but it appears to enhance LMP1’s ability to promote carcinogenesis in a 
transgenic mouse model [189]. LMP2A was shown to activate PI3K-AKT- and mTOR signaling in 
several cell lines, including a nasopharyngeal carcinoma line [22–24], and in vivo, in B-cells of LMP2 
transgenic mice [190]. The LMP2B splice variant lacks an N-terminal cytoplasmic domain and hence 
important signaling functions seen for LMP2A [191–193].  
Multiple KSHV-proteins have been implicated in activation of PI3K-, AKT- and/or mTOR 
signaling. In particular, the viral G-protein coupled receptor homolog (vGPCR), a lytic gene, signals to 
mTORC1 via PI3K [97], a PI3K isoform that is mainly expressed in white blood and endothelial cells 
and that is uniquely activated by GPCRs [97,194]. vGPCR signaling to mTORC1 drives endothelial 
cell proliferation [195] and mTORC1 signaling may in turn promote expression of the latent-to-lytic 
switch master regulator RTA [176]. The latter results may require further confirmation since the study 
is limited to pharmacologic inhibition of mTORC1 with rapamycin in one particular PEL cell line 
where rapamycin did not induce growth arrest. Moreover, the finding that mTORC1 is a positive 
regulator of RTA-driven lytic activation cannot be easily reconciled with another report discussed above, 
that provided evidence for autophagy promoting KSHV lytic replication, since autophagy is inhibited 
by mTORC1 [87]. Thus, additional studies are required to elucidate the regulatory connections between 
mTORC1, RTA and autophagy. In addition, KSHV activates PI3K-, AKT- and mTOR signaling in Cells 2012, 1  
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both B lymphocytes [78] and endothelial cells [79,80] via its K1 protein, a constitutively active B-cell 
receptor homolog which is predominantly expressed during lytic replication [196–198].  
Figure 3. Autophagy regulation via nutrient- and growth factor sensitive signaling 
pathways and points of interference by viral proteins.  
 
This figure gives a simplified overview of the cell’s nutrient and growth-factor regulated cellular signaling 
pathways: (1) the PI3K pathway and its important signaling mediators AKT, the TSC1/2 GTPase activating 
complex for the GTPase Rheb, which activates mTORC1, and mTORC1 (note: individual complex proteins 
have been omitted for clarity); (2) the RAF-MEK-ERK MAPK-module and (3) the AMPK pathway. 
Interactions of these pathways with the p53 tumor suppressor, which is commonly inactivated by viral 
oncoproteins are also shown. These pathways are directly connected to the autophagy machinery via the 
ULK1-kinase complex and Beclin-1. See main text for additional details. See Figure 4 for AKT- and TAK1 
regulation of NF-B signaling, regulation of Beclin-1 by JNK signaling and viral modulators of the JNK 
pathway, as well as additional upstream regulators, downstream mediators and viral modulators of TAK1 
signaling. Mechanistic details on how viral proteins interfere with nutrient- and growth factor-regulated 
signaling pathways are discussed in the text, except for the following: HBV LHBs and MHBs
t signal to RAF 
via protein kinase C (PKC) [31]. HBx can also activate PKC [199]. HCV NS5A does not directly target 
mTOR but its regulator FKBP38 [200] and may inhibit ERK signaling by interacting with GRB2 [50,51]. 
Question marks indicate that it is currently unclear whether DAPK-phosphorylation of Beclin-1 occurs 
physiologically, which HCV-protein is involved in inhibition of PP2A, which KSHV protein is involved in 
inhibition of AMPK, and whether HPV E7 activates AKT via an retinoblastoma protein dependent or -
independent mechanism involving PP2A [62,63]. Light grey rounded rectangles—host cell kinases; light grey 
ovals—host cell transcription factors; dark grey rounded rectangles—other host cell proteins; colored 
hexagons—viral proteins; : activation; to : inhibition. -: no general consensus in the literature on 
activation/inhibition, outcome may be cell type specific. Cells 2012, 1  
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Modulation of PI3K-AKT-mTOR signaling may also play an important role in HBV-associated liver 
carcinogenesis. Studies in cultured cells and in clinical samples collectively suggest a model whereby 
PI3K-AKT-mTOR signaling is initially activated by the HBV large surface protein LHBs, whereas at later 
stages, PI3K-AKT-mTOR signaling suppresses LHBs-expression and HBV-replication [32–34,201]. 
The situation is similar in HCV infection, in that mTOR signaling suppresses viral replication, even 
though the virus can increase mTOR activity [202–204]. The NS5A protein may play an important role in 
this, since it has been reported to activate mTORC1 signaling via both PI3K-AKT-dependent [49,50,205] 
and independent mechanisms [200]. On the other hand, NS5A was also found to be phosphorylated in 
a rapamycin-sensitive manner when ectopically expressed in COS-1 cells, suggesting that it functions 
downstream of mTORC1 [206]. Other HCV proteins activating AKT signaling include NS4B and  
core [46]. It is interesting to note that the group that reported that NS4B is sufficient to induce 
autophagic markers did not observe alterations in mTORC1-activity by NS4B [48].  
In cells expressing the HPV oncoprotein E6, mTORC1-activity is sustained even under conditions 
of growth factor deprivation [58,59]. Although controversial reports exist in the literature regarding the 
underlying mechanism [59,207], studies conducted in a physiologically relevant cellular system, 
human foreskin keratinocytes (HFKs), suggest that this is due to E6 sustaining the activity of AKT, 
which stimulates mTORC1 [59]. Whether this restrains autophagy-induction under these conditions 
remains to be investigated. The second HPV oncoprotein, E7 also has been reported to activate AKT 
signaling in several cell types including HFKs [62,63]. Although this is predicted to inhibit autophagy, 
E7 was found to induce an autophagy-like process in normal human keratinocytes even when the cells 
were grown in normal medium [68]. Additional studies are required to define the mechanism by which 
HPV E7 expression activates the autophagy machinery, although it has been speculated that it may 
arise as a consequence of metabolic stress [208], potentially due to induction of the Warburg effect by 
the HPV E7 protein [209] and the concomitant decrease in ATP production. Moreover, it will be 
interesting to investigate if autophagy is deregulated in cervical cancer cells, which co-express the E6 
and E7 oncoproteins that may have opposing effects on autophagy-like processes.  
Similar to HPV E6, the HTLV-1 oncoprotein Tax allows for sustained AKT phosphorylation under 
low serum conditions, and this may be due to Tax interacting with the regulatory p85 subunit of  
PI3K [70]. Another study showed that Tax-conferred growth factor independence through   
mTORC1 [71]. 
Currently, there are no reports in the literature that specifically address interference with autophagy 
by the most recently discovered tumor virus, MCPyV. Yet, the MCPyV small T-antigen, which is 
regularly expressed in MCPyV-positive tumors [75] was shown to increase phosphorylation of   
the two mTORC1 effectors and substrates, 4E-BP1 and S6K, potentially by inhibiting their 
dephosphorylation [75]. It is interesting to note that in another recent study, activating mutations in 
PI3K were detected almost exclusively in MCPyV negative Merkel cell carcinoma specimens [210]. 
This underscores the importance of PI3K signaling and its downstream targets such as mTORC1 for 
MCC development and supports the model that MCPyV has evolved strategies to activate this   
critical pathway. Cells 2012, 1  
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3.2.2. ERK Signaling 
The ERK pathway represents the prototypical example of a mitogen-activated protein kinase 
(MAPK) cascade where ERK (a MAPK) is activated by MEK, a MAPK kinase (MAPKK), which in 
turn is activated by RAF, a MAPKK kinase (MAPKKK). RAF is typically activated by the small 
GTPase Ras downstream of receptor tyrosine protein kinases [211] (Figure 3). Many effects of ERK 
signaling are cell type and context dependent [212], and this may include its role in autophagy 
regulation. ERK signaling contributes to mTORC1 activation, which suppresses autophagy [104].   
In addition, at least in certain cell types, the ERK-substrate 90 kD ribosomal protein S6 kinase (RSK) 
can inhibit death-associated protein kinase (DAPK), a potential positive regulator of Beclin-1 
dependent autophagy [213,214], and both ERK and RSK can inhibit the Ser/Thr-kinase LKB1 [215] 
and thus interfere with activation of the pro-autophagic kinase AMPK (see below) [216]. Finally, ERK 
may modulate autophagy via RSK-dependent activation of NF-B signaling [217], which is discussed 
in more detail below. 
Tumor viruses that interfere with ERK signaling include KSHV, HBV, HCV and HPV. KSHV 
modulation of ERK signaling has been studied in the context of lytic gene regulation. KSHV ORF45, 
an immediate early gene expressed during primary infection as well as reactivation [218] was   
shown to promote lytic gene expression by recruiting ERK and its substrate RSK into a common 
complex and  by sustaining the enzymatic activity of both kinases [219]. In addition, several   
splice variants of the transmembrane protein K15 were also reported to activate the ERK pathway [81]. 
HBV activates  the  Ras-RAF-MEK-ERK pathway via HBx and the large and middle surface   
antigens [30–32,51,61,220–222] and HPV via its E6 and E7 oncoproteins [61]. For HCV, evidence has 
been provided that core and NS3 activate ERK signaling [37,38] while NS5A may suppress this 
pathway [50,51]. For any of the viruses discussed here, KSHV, HBV, HCV, and HPV, it remains to be 
examined whether their interference with ERK signaling affects autophagy.  
3.2.3. AMPK-Signaling 
The AMP-activated protein kinase, AMPK, is a major cellular energy sensor and may positively 
regulate autophagy by inhibiting mTORC1 (for reviews, see [104,216]). However, several studies 
demonstrated that AMPK can also directly target the autophagy machinery. AMPK associates with and 
phosphorylates the autophagy-initiating kinase ULK1 [223–226] (Figure 3). AMPK-dependent 
phosphorylation of ULK1 may be important for autophagosome biogenesis since it is required for 
correct intracellular localization of mAtg9, a putative membrane carrier protein [227,228]. AMPK 
activity is modulated by the cellular ATP/AMP ratio and requires phosphorylation by an upstream 
kinase, such as LKB1, CamKK or potentially TAK1, which also plays an important role in NF-B 
activation [229]. All three of these kinases have been reported to mediate autophagy via AMPK, at 
least in specific cell lines and contexts [230–232]. Moreover, AMPK-dependent autophagy induction 
seems to require p53, which, as discussed below, is commonly inactivated by tumor viruses [233].  
Reports explicitly connecting AMPK or one of its upstream kinases to human tumor viruses and 
autophagy are scarce in the literature. Expression of simian vacuolating virus 40 (SV40) small T 
antigen has been demonstrated to inhibit cell death in glucose deprived cultured cells by activating Cells 2012, 1  
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AMPK and increasing autophagy [234]. However, whether small T antigens of other polyomaviruses, 
such as that of the carcinogenic MCPyV can also activate AMPK remains to be determined. A recent 
study detected no evidence for AMPK activation in EBV-positive B cells that underwent autophagy in 
response to NF-B inhibition [16], yet it cannot be ruled out that AMPK may still be important in this 
setting, since even basal activity of AMPK is sufficient for induction of autophagy [235,236].  
However, beyond the specific context of autophagy, there is increasing evidence for crosstalk 
between AMPK signaling and viral infection, including infection by tumor viruses [237]. In particular, 
AMPK-inhibition was observed in KSHV-infected endothelial cells [79]. Moreover, in Huh-7 cells, 
HCV infection or the presence of a subgenomic replicon decreased AMPK-activity [238]. Conversely, 
pharmacologic AMPK activation blocked viral replication [238]. Since AMPK is an inhibitor of lipid 
biosynthesis, AMPK activation may block formation of a membranous web that is critically important 
for HCV replication [216,239,240]. However, since HCV induces, rather than inhibits, formation of 
autophagic vesicles [48,55,142,146,147,156], it remains to be determined whether and under which 
conditions HCV-modulation of AMPK affects autophagy in infected cells. 
Given that AMPK- and AKT-mTOR signaling have opposing effects on cell physiology, some 
findings on the biochemical and biological activities of these pathways in the context of   
HCV-infection cannot be easily reconciled. AMPK activation, for instance, which decreases   
HCV-replication, should result in mTOR-inhibition. Yet, as was pointed out above, mTOR is also a 
negative regulator of HCV-replication, and its inhibition should favor HCV replication. This suggests 
that AMPK and mTOR inhibit HCV-replication through different molecular mechanisms and that 
maximum replication should occur when both AMPK- and mTOR signaling are suppressed. 
Interestingly, a study that investigated biopsies of chronically hepatitis C infected liver tissues showed 
increased expression of protein phosphatase 2A (PP2A), which negatively regulates both the AMPK- 
and the AKT-mTOR pathway in cultured cells expressing HCV proteins [241]. Clearly, additional 
studies are required to further characterize the profound HCV-induced changes in the host cell 
signaling pathways regulating cell growth, metabolism and autophagy that are suggested by the 
currently available data.  
Several viral oncoproteins such as EBV LMP1 [15], KSHV vGPCR [242], HBx [243] and HTLV-1 
Tax [69] were shown to signal through the potential AMPK-activating kinase TAK1. TAK1-AMPK 
connections in the context of these viral proteins, however, have not been examined.  
3.2.4. Other Kinases Involved in Starvation-Induced Autophagy 
Kinases other than AMPK and mTOR have also been implicated in starvation-induced autophagy. 
Positive regulators include the IKK kinase complex (discussed in greater detail below), which was 
found to be important for efficient upregulation of autophagy in response to starvation [244] and JNK1 
(see above), which upon starvation releases Beclin-1 from an inhibitory complex with Bcl-2 [103]. The 
p38 kinase is a negative regulator of both basal and starvation induced autophagy and modulates 
trafficking of the putative membrane carrier protein mAtg9 [102]. Viral oncoproteins upregulating p38 
signaling include EBV LMP1 [17,21], KSHV vGPCR [86], K15 [81] and ORF49 [85], the HBV 
protein HBx [29], HCV core and NS3 [37,38], the HPV E5 protein [56] and HTLV-1 Tax [69]. 
Conversely, HCV NS5A inhibited p38-activity [53]. JNK and p38 may also modulate autophagy Cells 2012, 1  
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through activating NF-B (see below). Lastly there is evidence from studies in yeast which require 
further confirmation in mammalian cells that PKR, a kinase targeted by many viruses because of its 
function in antiviral immune signaling (see above) may also play a role in starvation-induced 
autophagy [140].  
3.2.5. The p53 Tumor Suppressor 
The p53 tumor suppressor also has an important role in controlling metabolic stress [245]. In 
response to various autophagy-inducing stimuli, including nutrient-deprivation and mTOR-inhibition, 
nuclear p53 induces transcription of genes that positively regulate autophagy such as the lysosomal 
protein Damage-Regulated Autophagy Modulator (DRAM) [246] and Sestrin 2 [247,248]. Moreover, 
p53 transcriptionally activates negative regulators of the PI3K-AKT-mTOR signaling pathway such as 
AMPK, TSC2, PTEN and IGF-BP3, at least in certain cell types and in response to particular 
stressors [249]. A notable exception to the general trend that p53-target genes promote autophagy is 
the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR), a fructose-2,6-bisphosphatase [250] 
that inhibits autophagy by decreasing ROS-levels under conditions of nutrient starvation or metabolic 
stress [251]. In contrast to nuclear p53, cytoplasmic p53 mutants inhibit autophagy by interacting with 
FIP200, a component of the autophagy-initiating ULK1-kinase complex [252,253].  
Various viral oncoproteins have been reported to interfere with p53 function but whether this 
contributes to autophagy modulation by any of the human tumor viruses has not been examined yet. 
The most prominent examples include SV40 large T antigen, Adenovirus E1b and HPV E6, which all 
form complexes with p53 and functionally inactivate it (reviewed in [254]). In particular, HPV E6 
recruits the host cell encoded E3 ubiquitin ligase UBE3A (E6AP) to target p53 for ubiquitination and 
proteasomal degradation [60,255,256]. The immediate benefit of E6-mediated p53-inactivation for   
the virus presumably consists in abrogation of the p53-dependent apoptotic response which otherwise 
would be triggered to counteract excessive cell proliferation driven by E7 [5]. In addition,   
KSHV latency associated nuclear antigen (LANA) has been reported to interact with p53 and inhibit 
its transcriptional activity [82]. The HBx protein was reported to interact with p53 in HBV-positive 
HCC tissue lysates [28], and there have also been reports for interactions of the HCV proteins   
core [42,43,45], NS3 [41] and NS5A with p53 [44]. HTLV-1 Tax also inhibits p53 transcriptional 
activity [73, 257–259]. Even though p53 was originally discovered through its interaction with SV40 
large T antigen [257] there is no evidence that MCPyV large T antigen associates with p53. 
3.2.6. NF-B Signaling 
Nuclear factor B transcription factors are executing the biological activities of multiple   
stress-sensitive signaling pathways, including immune signaling pathways (Figure 4). Not surprisingly, 
they regulate expression of a broad variety of genes related to immunity, cell proliferation, 
differentiation and survival [139,229]. An overview of the NF-B signaling network as it pertains to 
autophagy is given in Figure 4. 
There is complex and reciprocal regulation of NF-B signaling and autophagy and both activation 
and suppression of one by the other have been observed. Many of the reported effects, however, may 
be specific to the cell type and/or the autophagy-modulating treatment applied. For example, in   Cells 2012, 1  
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HTLV-1 transformed cells and ATL cell lines, autophagy induced by Geldanamycin treatment 
inhibited NF-B signaling by selectively degrading IKK and NIK [260,261]. On the other hand, in 
mouse embryonic fibroblasts (MEFs), Atg-proteins ATG5, ATG7, Beclin-1 and VPS34 were required 
for activation of NF-B by tumor necrosis factor- (TNF) [262]. Conversely, the NF-B family 
member p65 positively regulated basal autophagy by transactivating the Beclin-1 promoter in   
T-cells [263]. However, NF-B suppressed TNF-, but not starvation-induced autophagy in Ewing 
sarcoma-cells [264]. Finally, a recent study suggested that NF-B signaling can be activated in parallel 
with autophagy by pro-autophagic stimuli via a mechanism that involves the TAK1-binding proteins 2 
and 3 (TAB2/3) switching from binding and inhibiting Beclin-1 under basal conditions to associating 
and activating TAK1 [265]. Moreover, the NF-B-regulating kinase IKK can promote autophagy 
independently of the transcription factor NF-B. AMPK and JNK appeared to be important downstream 
mediators of IKK in this context [244]. Conversely, in B cell lymphomas, IKK inhibited autophagy as 
a consequence of promoting glucose uptake via parallel activation of NF-B and AKT [16].  
Figure 4. Autophagy regulation via the NF-B pathway, and points of interference by  
viral proteins.  
This figure gives a simplified overview of the cellular signaling pathways that regulate NF-B transcription 
factors. These transcription factors function as homo- or heterodimers formed by the five proteins of the  
NF-B/Rel-family: NF-B1/p50, which is generated by proteolytic cleavage of its precursor p105 (omitted 
for clarity), NF-B2/p52 generated by cleavage of the precursor p100, RelA/p65, RelB and c-Rel. The Cells 2012, 1  
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canonical NF-B pathway is triggered by B-cell-, T-cell, cytokine-, growth factor- or Toll-like receptor 
signaling, which lead to activation of the inhibitor of B kinase (IKK) complex in the cytoplasm. This 
complex consists of the catalytic subunits IKK and IKK and the negative regulatory subunit IKK/NEMO 
(NF-B essential modulator). IKK activation often also requires the transforming growth factor -activated 
protein kinase 1 (TAK1). IKK complexes phosphorylate an inhibitor of B (IB) protein, which binds   
NF-B dimers and retains them in the cytoplasm. Phosphorylation by IKK induces ubiquitination and 
proteasomal degradation of IBs and releases NF-B dimers, which subsequently undergo additional 
phosphorylation and acetylation events (omitted for clarity) and translocate to the nucleus to activate 
transcription of their target genes. Non-canonical NF-B activation involves NF-B-inducible kinase (NIK) 
mediated activation of IKK homodimers, which then phosphorylate the NF-B2/p100 precursor. This 
allows proteolytic processing of p100 to p52 which associates with RelB to form a functional transcription 
factor complex that enters the nucleus [229]. See main text for additional details and Figure 3 for additional 
autophagy-regulating pathways downstream of AKT and TAK1 and for upstream regulation of RSK. 
Specific tumor virus derived surface antigens/pathogen associate molecular patterns (PAMPs) activating the 
immune receptors shown in this figure have been omitted for clarity. Mechanistic details on how viral 
proteins interfere with NF-B signaling have been included and are discussed in the text, except for the 
following: HTLV-1 Tax and KSHV vFLIP interact with IKK [266–270] and stimulate p100 expression and 
processing independently of NIK, whereas Tax may also directly interact with IKK and p100 [271–273]. 
Question marks indicate that it is not clear at the moment where HPV E7 interferes with TNF- and   
TGF-receptor signaling, and by which mechanism KSHV ORF75 activates NF-B-dependent transcription. 
Light grey rounded rectangles—host cell kinases; light grey ovals—host cell transcription factors; dark grey 
rounded rectangles—other host cell proteins; colored hexagons—viral proteins; colored box—viral 
microRNA; : activation; to : inhibition. -: no general consensus in the literature on activation/inhibition; 
outcome may be cell type specific. 
 
The NF-B pathway is a common target of several of the human tumor viruses. NF-B signaling 
plays a central role throughout the entire life cycle of the -herpesviruses EBV and KSHV and is 
constitutively activated during latency [274]. This is largely due to the action of LMP1 and vFLIP, in 
EBV- and KSHV infected cells, respectively [92,274,275]. LMP1 activation of NF-B signaling was 
shown to suppress autophagy in B cells, a natural host of EBV [16], while vFLIP was shown to inhibit 
autophagy by targeting ATG3 [90] (see above). So far, no studies have implicated activation of NF-B 
signaling in autophagy regulation by vFLIP. EBV and KSHV each express additional regulators of 
NF-B signaling [274]. The EBV immediate early protein ZTA, which is involved in the latent-to-lytic 
switch, inhibits the transcriptional activity of p65 [25], while KSHV microRNA miR-K1 and the 
vGPCR enhance NF-B activity [91,93–95]. In addition, ORF75 and K15 may activate NF-B 
signaling and vIRF3 acts as a suppressor [93,100]. The effect of KSHV K1 on NF-B activity is 
controversial in the literature [93,100] 
There is evidence that HBV HBx and a truncated form of the middle surface antigen (MHBs
t) can 
activate NF-B-dependent transcription, and this may contribute to enhanced tumor burden in MHBs
t 
transgenic mice [31,35]. In the context of HCV infection, NF-B, along with p38, JNK and ERK1/2 is 
activated as a consequence of ROS production in tissue culture cells [276]. This causes increased 
production of TGF1 [276], a cytokine that promotes autophagy in HCC cell lines [277]. Evidence has 
been provided for NS4B [40] and NS5A [39], respectively, being important for the induction of 
oxidative stress by HCV. Additional HCV proteins shown to activate NF-B, potentially via the   Cells 2012, 1  
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JNK- and p38 pathways include core and NS3 [37]. There is no evidence that HBV and HCV 
modulate autophagy through these pathways. 
HPV positive cervical cancer cells are resistant to cytostatic effects of TNF [64] and TGF [65], 
which both act via NF-B and can activate autophagy. The E7 oncoprotein was shown to mediate the 
resistance to TNF and TGF-induced growth inhibition [64,65], and to suppress TNF-induced  
NF-B-activation when expressed in cervical epithelial cells [66]. Whether these effects of E7 are 
associated with altered host cell autophagy has not been determined.  
In HTLV-1 infected cells, NF-B is constitutively activated, predominantly via the non-canonical 
pathway. Even though the Tax oncoprotein upregulates both canonical and non-canonical NF-B 
signaling [74,76], the HTLV-1 encoded basic leucine zipper transcription factor HBZ selectively 
interferes with the canonical pathway [77]. As described in a previous paragraph, autophagy was found 
to inhibit NF-B signaling when HTLV-1 transformed cells and ATL-cell lines were treated with 
Geldanamycin, and this was suggested as a potential therapeutic strategy for ATL [278]. 
3.2.7. Signaling Pathways Activated by ER Stress  
The endoplasmic reticulum (ER) is the major cellular site for folding and maturation of secreted and 
transmembrane proteins. ER stress ensues when the number of unfolded and/or misfolded proteins that 
enter the ER exceeds the capacity of the ER chaperone machinery and triggers a regulatory response 
termed the unfolded protein response (UPR) that adjusts the ER work load to its folding/refolding 
capacity [279]. Moreover, the UPR also activates autophagy [139]. The signaling pathways that 
activate the UPR have been reviewed in detail elsewhere [279,280] and are outlined in Figure 5. 
Ectopic expression of the EBV oncoprotein LMP1 causes ER stress and activates all three arms of 
the UPR [19]. Conversely, PERK-dependent phosphorylation of elF2 and activation of ATF4 
increased LMP1 expression [19]. It is interesting to note that LMP1, when overexpressed at low levels, 
activates NF-B signaling rather than the UPR [19,281]. Importantly, however, vast variations in 
LMP1 levels spanning up to two orders of magnitude have been observed in EBV-infected clonal 
lymphoblast populations [282]. Moreover, induction of NF-B- and of PERK-elF2 signaling by 
LMP1 are independent and require different domains of LMP1 [19,282]. Interestingly, LMP1 also 
induces autophagy in a dose-dependent manner via the same domains that are also involved in   
UPR-activation, and autophagy mediates LMP1 degradation [18]. Thus, it is tempting to speculate that 
in fact ER stress caused by high levels of LMP1 is the trigger for autophagy upregulation [283]. 
Therefore, this pro-autophagic function of LMP1 when expressed at high levels is not inconsistent 
with a more recent study that reported suppression of autophagy by LMP1 signaling through 
IKK/NF-B due to increased capacity for glucose uptake [16]. Whether the second oncogenic -
herpesvirus, KSHV, also modulates ER stress and the UPR is not known at present. 
Ectopic expression of the HBV small surface protein SHBs was reported to be sufficient for the 
induction of autophagic markers, and the underlying mechanism involved upregulation of all three 
arms of the UPR [36]. In addition, mutant versions of the large surface protein LHBs were reported to 
induce ER stress, however, a potential effect on autophagy was not explicitly examined [33].  Cells 2012, 1  
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Figure 5. Autophagy regulation by ER stress/UPR signaling pathways and points of 
interference by viral proteins.  
The unfolded protein response (UPR) is triggered by endoplasmic reticulum (ER) stress and comprises three 
branches, each of which involves an ER transmembrane protein that senses the protein folding status in the 
ER and transduces this information to the cytosol. In the first branch, upon ER stress, the bifunctional inositol 
requiring enzyme 1 (IRE1) oligomerizes and autophosphorylates and thereby activates its endoribonuclease 
activity. This allows for splicing of an mRNA that encodes the transcription factor X-box binding protein 1 
(XBP1). The product of the spliced XBP1-mRNA (XBP1s), in turn, upregulates expression of UPR target 
genes, including chaperones and ER-associated degradation (ERAD) proteins. The product of the unspliced 
XBP1-mRNA (XBP1u) acts as a transcriptional repressor. In the second branch, ER stress triggers processing 
of activating transcription factor 6 (ATF6), which spans the ER membrane as an inactive precursor. 
Subsequently, the cytosolic ATF6 fragment enters the nucleus and activates expression of UPR target genes. 
In the third branch, ER stress activates PKR-like eIF2 kinase (PERK), which phosphorylates eIF2 and 
shuts down mRNA translation to reduce the number of proteins entering the ER. In parallel, PERK 
selectively promotes translation of certain stress-associated factors such as the ATF4 transcription factor. 
IRE1-, ATF6- and PERK signaling are activated independently but mutually reinforce each other, resulting in 
partially overlapping sets of UPR target genes. These UPR target genes include components of the autophagy 
machinery, and activation of autophagy allows degradation of ER domains that contain misfolded and 
aggregated proteins [284,285]. Note that eIF2 phosphorylation at the PERK-target site, S51, is also required 
for autophagy in response to other stressors, including viral infection, when eIF2 Ser51 is phosphorylated 
by PKR [140]. The molecular events that cause induction of autophagy downstream of eIF2 
phosphorylation are incompletely understood, with the exception of the above mentioned transcriptional 
effects on autophagy genes [139]. Additional mechanisms of autophagy induction by ER stress may include Cells 2012, 1  
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IRE1 signaling to JNK [286], a known kinase of Beclin-1, and PERK-mediated NF-B activation [287,288]. 
See Figure 4 for additional host cell signaling pathways and viral proteins modulating NF-B and JNK 
signaling, and events downstream of JNK-activation that contribute to autophagy-modulation. Mechanistic 
details on how viral proteins interfere with UPR signaling are discussed in the text. The question marks 
indicate that the finding of XBP1 increasing autophagy under basal conditions so far is limited to   
neurons [289]. This implies that XBP1 suppresses autophagy and gives rise to the hypothesis that the XBP1 
branch of the UPR functions to prevent excessive autophagy upon ER stress. Additional studies are required 
to test this possibility [289,290] and to clarify whether and under which conditions XBP1 activates or inhibits 
autophagy. Light grey rounded rectangles—host cell kinases; light grey ovals—host cell transcription factors; 
light grey boxes—host cell mRNAs; dark grey rounded rectangles—other host cell proteins; colored 
hexagons—viral proteins; : activation; to : inhibition. -: no general consensus in the literature on 
activation/inhibition; outcome may be cell type specific. 
 
Multiple  in vitro [48,142,146,291,292] and in vivo [293,294] studies collectively suggest that   
HCV-infection activates upstream regulators in all three branches of the UPR, but this does not lead to 
the induction of UPR-responsive genes [291-294]. Mechanistically, at least in the XBP1-branch of the 
UPR, the NS4B protein may be responsible for increasing XBP1-mRNA levels and splicing, but also 
for suppressing the transcriptional activator function of spliced XBP1 [291,292]. However, two studies 
provide evidence that the activators of the three UPR signaling pathways, PERK, ATF6 and IRE1, as well 
as a PERK-target gene, the transcription factor C/EBP-homologous protein (CHOP), play an important 
role upstream of the HCV-induced autophagy-like process in promoting viral replication [142,146] and 
in suppressing the antiviral immune response [142]. Thus, additional studies are required to elucidate 
how HCV perturbs UPR signaling and autophagy in infected cells. 
Little is known regarding modulation of ER-stress pathways by high-risk HPV proteins. There is 
evidence that in human keratinocytes, E5, and also E6/E7 suppress activation of the ER stress factor 
XBP1 under basal conditions, i.e., in the absence of ER- or other forms of stress [57]. Of note, XBP1 
appears to suppress autophagy under these conditions, at least in neurons, giving rise to the hypothesis 
that suppression of XBP1 signaling by HPV-proteins increases basal autophagy [289,290]. Although 
basal autophagy levels may indeed be elevated in HPV positive cells [68], additional studies are 
required to clarify the relationship between HPV proteins, ER stress signaling pathways and autophagy. 
Conversely, there is evidence that HTLV-1 via its Tax-protein upregulates XBP1 transcription (but 
not splicing) in unstressed cells, and vice versa. The mechanism may involve physical interaction 
between Tax and the protein products of both the unspliced and the spliced XBP1-mRNAs [72]. 
While Tax expression increased UPR signaling under basal conditions, ER stress did not increase   
HTLV1-expression despite increasing XBP1-transcription and splicing. It remains to be determined 
whether the Tax-XBP1-interaction affects basal- or stress-induced autophagy in HTLV1-infected cells.  
4. Concluding Remarks
By mediating turnover and recycling of macromolecular and supramolecular intracellular structures, 
autophagy plays a central role in maintaining cellular homeostasis under physiologic conditions as 
well as under conditions of stress. Accordingly, this process is regulated by virtually all cellular 
signaling pathways that sense cell-intrinsic or environmental perturbations. These networks include 
immune signaling pathways and indeed, autophagy is emerging as an important defense mechanism Cells 2012, 1  
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against pathogens, including viruses. A small subset of viruses is known to cause or at least contribute 
to a variety of human cancers and a large number of studies support the notion that infection with these 
viruses disturbs signaling networks far beyond pathways primarily associated with immunity. Indeed, 
signaling pathways that primarily control cell growth, proliferation and survival, i.e., processes that are 
generally deregulated in cancer cells, are affected as well. These pathways are also connected to 
regulation of autophagy. With exception of the most recently discovered tumor virus, MCPyV, there is 
evidence that all of the established human tumor viruses induce hallmarks of autophagy in their host 
cells. Whether this represents genuine induction of autophagy has not been formally demonstrated in 
all cases. Only very few tumor virus proteins have been demonstrated to interact directly with 
autophagy-regulating proteins, and many studies reporting interference with upstream signaling 
pathways capable of modulating autophagy did not explicitly examine potential effects on autophagy. 
At least for some of the human tumor viruses, additional studies are necessary to further substantiate 
their connection to autophagy or to autophagy-like processes, to further elucidate the underlying 
molecular mechanisms and to provide answers to the key questions of how host cell autophagy affects 
the viral life cycle and how modulation of the autophagy machinery contributes to the development of 
virus-induced cancers. The current literature does not provide a uniform picture of whether viruses in 
general are threatened by or benefit from a functional host cell autophagy machinery and whether they 
have evolved to inhibit autophagy (or at least some steps in that process) or to exploit it to their own 
advantage. The answers to these questions may differ for different human tumor viruses. 
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